Can-Fite BioPharma Launches Phase IIa Clinical Trial for Pancreatic Cancer
Recently, the International biotechnology sector received exciting news as Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) announced a major milestone in its efforts to combat pancreatic cancer. The company successfully dosed the first patient in a Phase IIa clinical trial targeting advanced pancreatic adenocarcinoma.
Understanding the Significance of This Trial
The Phase IIa study, registered as NCT06387342, aims to evaluate the efficacy and safety of Namodenoson, a proprietary small molecule oral drug that has generated considerable interest in the oncology field. This trial's unique focus is essential for addressing an area of significant unmet medical need, as existing treatment options for late-stage pancreatic cancer remain limited. Dr. Michael Silverman, Can-Fite’s Medical Officer, expressed enthusiasm regarding the enrollment of the first patient, underscoring the hope of demonstrating Namodenoson's potential benefits in this challenging patient group.
Details of the Clinical Trial
The multicenter, open-label trial is structured to enroll approximately 20 evaluable patients who have seen disease progression after first-line therapy. Each patient will receive 25 mg of Namodenoson, taken orally twice daily over 28-day cycles. The primary aim of this clinical trial is to delineate the safety profile of Namodenoson, while secondary objectives include measuring clinical activity through various endpoints such as the Objective Response Rate (ORR), Progression-Free Survival (PFS), Disease Control Rate (DCR), Duration of Response (DoR), and Overall Survival (OS).
Key Opinion Leaders in Cancer Research
The trial is under the guidance of notable figures in oncology. Dr. Salomon Stemmer is leading the study at the Institute of Oncology, Rabin Medical Center, while Dr. Al Mutar from the UT Southwestern Medical Center in the US collaborates closely. Their expertise reinforces the potential implications of this study in advancing treatment options for patients affected by pancreatic cancer.
Exploring the Potential of Namodenoson
Namodenoson is noteworthy due to its selective action on the A3 adenosine receptor (A3AR), which is prominently expressed in tumor cells and allows for a focused therapeutic approach. Previous studies have shown promising results for Namodenoson in treating liver diseases, reinforcing its potential efficacy in oncology, particularly in cancers like hepatocellular carcinoma. With an excellent safety profile evidenced by its use in over 1,600 patients across clinical trials, Namodenoson is an exciting addition to the fight against cancer.
Can-Fite BioPharma’s Broader Mission
Can-Fite BioPharma (NYSE: CANF) is dedicated to harnessing its innovative drug development platform to tackle significant health challenges in oncology, as well as liver and inflammatory diseases. The company’s ongoing trials reflect its commitment to finding solutions in multiple high-need markets.
Recent Advancements in Clinical Trials
In addition to the pancreatic cancer trials, Can-Fite is making strides with its lead drug candidate, Piclidenoson, which recently shared promising topline results in a Phase III trial for psoriasis. Furthermore, Namodenoson is under investigation in a Phase IIb trial for managing metabolic-associated fatty liver disease, indicating Can-Fite’s extensive focus across disease treatment avenues.
Looking Ahead
The granted Orphan Drug Designation by the U.S. FDA for Namodenoson adds another positive note to Can-Fite’s innovation strategy. This recognition underscores the drug's potential in treating serious conditions, and it marks a critical step toward advancing through the regulatory pathways that can expedite its access to patients who need it the most.
Frequently Asked Questions
1. What is Namodenoson?
Namodenoson is an oral small-molecule drug with selective activity on the A3 adenosine receptor, being studied for its efficacy in treating pancreatic cancer and other conditions.
2. What are the primary goals of the Phase IIa trial?
The primary goals are to evaluate the safety profile of Namodenoson and its clinical activity through various cancer response measures.
3. Who is leading the pancreatic cancer clinical trial?
Dr. Salomon Stemmer and Dr. Al Mutar are the leading researchers conducting this study at their respective medical institutions.
4. How many patients will be enrolled in the trial?
Approximately 20 evaluable patients with advanced pancreatic adenocarcinoma will be enrolled in the study.
5. What other trials is Can-Fite conducting?
Can-Fite is also advancing trials for its psoriasis drug Piclidenoson and for Namodenoson in liver disease treatment.
